HR-Positive Metastatic Breast Cancer — A Discussion and Debate on First- and Second-Line Therapy

Featuring perspectives from Dr Sara A Hurvitz and Dr Virginia Kaklamani, including the following topics:

Introduction: Which Biomarkers and When (0:00)

Optimizing First-Line Therapy for Patients with Hormone Receptor (HR)-Positive Metastatic Breast Cancer (mBC) (5:31)

SERENA-6 Trial (19:44)

Inavolisib (23:08)

Management of HR-Positive mBC Progressing on a CDK4/6 Inhibitor and Endocrine Therapy (31:46)

Selective Estrogen Receptor Degraders (41:15)

AKT (46:13)

CME information and select publications

The skinny

The skinny isn't ready yet — notes appear once the transcript is processed.